Credit Suisse Group Analysts Give Bayer (BAYN) a €95.00 Price Target
Credit Suisse Group set a €95.00 ($110.47) price target on Bayer (FRA:BAYN) in a research note issued to investors on Thursday, September 6th. The brokerage currently has a buy rating on the healthcare company’s stock.
Other research analysts have also recently issued research reports about the stock. UBS Group set a €130.00 ($151.16) price target on shares of Bayer and gave the company a buy rating in a research report on Friday, August 17th. Baader Bank set a €123.00 ($143.02) price objective on shares of Bayer and gave the company a buy rating in a report on Wednesday, August 22nd. Sanford C. Bernstein set a €115.00 ($133.72) price objective on shares of Bayer and gave the company a buy rating in a report on Wednesday, September 5th. Citigroup set a €132.00 ($153.49) price objective on shares of Bayer and gave the company a buy rating in a report on Monday, June 18th. Finally, Independent Research set a €105.00 ($122.09) price objective on shares of Bayer and gave the company a neutral rating in a report on Monday, June 4th. Ten equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of €101.36 ($117.86).
Shares of BAYN stock traded up €1.67 ($1.94) on Thursday, hitting €71.82 ($83.51). 3,761,768 shares of the stock traded hands. Bayer has a twelve month low of €91.58 ($106.49) and a twelve month high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Read More: How to Use the New Google Finance Tool
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.